Media - Abzena


MHC Associated Peptide Proteomics

Case Study MAPPs for Vaccine Design To identify MHC class I presented antigens derived from influenza strain H1N1, two[...]



World ADC Europe

26 March 2018

This is the 8th staging of Europe’s leading antibody-drug conjugation conference. The meeting is Europe’s leading[...] Read more

The Future of Swedish & Danish Life Science

22 March 2018

Join the Abzena team to celebrate the success of the Nordic life science industry and explore the opportunity to benefit[...] Read more


Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial development[...] Read more


Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group[...] Read more

Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena

Cambridge, UK, 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and[...] Read more


We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Interested in our services? Get In Touch